Compare GMM & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | INBS |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 5.7M |
| IPO Year | 2022 | 2019 |
| Metric | GMM | INBS |
|---|---|---|
| Price | $2.73 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.9M | 56.6K |
| Earning Date | 01-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,980,484.00 |
| Revenue This Year | N/A | $778.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.54 |
| 52 Week High | $4.75 | $24.90 |
| Indicator | GMM | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 63.17 | 37.38 |
| Support Level | $1.11 | $0.59 |
| Resistance Level | $4.75 | $2.46 |
| Average True Range (ATR) | 0.47 | 0.14 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 57.62 | 18.52 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.